← Back to patent-cliff list
Icenticaftor
Tier C — Watch / tradeIcenticaftor
Novartis
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CFTR
Indications (approved)：Bronchiectasis, Chronic obstructive pulmonary disease, 肝功能衰竭, Cystic fibrosis
Regional status
US
Phase II
2012-07-31
EU
Phase II
2012-07-31
China
Phase II
2021-02-02
Japan
Phase II
2019-09-12
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Icenticaftor?
Approved indications include: Bronchiectasis, Chronic obstructive pulmonary disease, 肝功能衰竭, Cystic fibrosis.
When does the Icenticaftor patent expire?
No public expiry year is available for Icenticaftor yet; this page updates once verified.
How do I get a quote for Icenticaftor intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-18